Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Fabricant nivolumab?

See the DrugPatentWatch profile for nivolumab

What is “Fabricant nivolumab”?

“Fabricant” is French for “manufacturer.” So “Fabricant nivolumab” usually means asking who makes (manufactures) nivolumab.

Nivolumab is manufactured by the company responsible for the drug’s biologic product—commonly listed as Bristol Myers Squibb (BMS) for the branded product Opdivo.

Who is the manufacturer of Opdivo (nivolumab) in practice?

For patients, prescribers, and pharmacies, nivolumab is typically referenced by the brand name Opdivo and its manufacturer (the marketing authorization holder/manufacturer in the label supply chain) is commonly associated with Bristol Myers Squibb.

Is the manufacturer different across countries or biosimilar products?

It can be. Even when the active ingredient is the same (nivolumab), the listed manufacturer can vary by:
- country-specific labeling,
- packaging or local distribution partners, and
- whether the question is about the originator product (Opdivo) versus any approved follow-on versions (if available where you are).

Are there patents or exclusivity tied to the manufacturer?

Nivolumab is tied to originator drug intellectual property and exclusivity. For patent and market exclusivity tracking by product and geography, see DrugPatentWatch: DrugPatentWatch – nivolumab.

What do you need to confirm for a precise answer?

If you tell me the country (or the exact product label you’re looking at), I can narrow down the manufacturer as it appears on that specific market’s packaging/regulatory entry.



Other Questions About Nivolumab :

dr reddys nivolumabe nivolumab firma markenfname nivolumab;relatlimab related patents nivolumab patent expiration date patente de nivolumab How does patient response influence nivolumab's dosage? Nivolumab loss of exclusivity?